Do you know what it’s like to sit in a meeting and learn that something you hold close as a fundamental principle is probably not as fundamentally true as you thought?

That’s the way I felt earlier this week while attending a meeting on the quality of pharmaceuticals, sponsored by the Food and Drug Administration and Duke University’s Margolis Center for Health Policy.

The meeting—a recording of which is available online—brought together thought leaders from the FDA, Duke, hospital systems, pharmaceutical companies, patient advocates, and others, including the American Cancer Society to discuss issues surrounding the quality assurance of the medicines we rely on every day.

See Also

• 2021 Guide: 5 Reasons to Outsource Your Medical Billing
• How 3D Printing Can Revamp Personalised Surgery
• Patients Don't Need Quick Diagnoses. They Need Accurate Ones.
• DrChrono’s Open FHIR API Enables Patients to Transfer Records to Apple Health
• How Artificial Intelligence Is Optimizing Revenue Cycle Management